This led us to hypothesize that there are two pools of nuclear AR protein in prostate cancer cells: one bound to chromatin where it functions as a transcription factor and its activity is sensitive to actinomycin D, and the other that is telomere-bound where it functions in maintaining telomere stability independent of AR transcriptional activity and is resistant to actinomycin D. The gene discussed is AR; the disease is prostate cancer.